Investing in unprofitable companies can be lucrative, but risky due to cash burn. Aligos Therapeutics had a 17-month cash runway in March 2024, with concerns about its future cash position. While it reduced cash burn slightly, growth prospects remain uncertain.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing